Abstract
No public abstract is available from the verified source records.
Hideyuki Akaza, K. H. Kurth, Richard Dafydd Williams, Shiro Hinotsu, Michael A S Jewett, Katsusuke Naito, K Okada, Paul F. Schellhammer, Roland F. van Velthoven, Johannes Alfred Witjes
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Prognostic factors in superficial bladder cancer
1986
Prognostic factors in Ta, T1 (superficial) bladder cancer
1993
Intravesical chemotherapy and immunotherapy
10.1111/j.1442-2042.1995.tb00476.x · 1995
Urothelial susceptibility to tumor cell implantation. Influence of cauterization
10.1002/1097-0142(19800901)46:5<1158::aid-cncr2820460514>3.0.co;2-e · 1980
Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy
1976
The etiology of bladder cancer. Are there any new clues or predictors of behavior?
10.1111/j.1442-2042.1995.tb00481.x · 1995
Molecular epidemiology and retinoid chemoprevention of head and neck cancer
10.1093/jnci/89.3.199 · 1997
Multistage carcinogenesis in the urinary bladder
10.1093/oxfordjournals.bmb.a071611 · 1980
Persistence of carcinogen-altered cell population in rat urothelium which can be promoted to tumors by chronic inflammatory stimulus
1994
Clinical study on urothelial tumors of dye workers in Wakayama city
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/s0022-5347(17)38151-x · 1991
Present states and problems of intravesical instillation against superficial bladder cancer
1988
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Strategy for prevention of recurrence of superficial bladder cancer
10.1055/s-2008-1055634 · 1996
Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumors
10.1046/j.1464-410x.1997.00142.x · 1997
Bacillus calmette-guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder
10.1002/1097-0142(19950115)75:2<552::aid-cncr2820750219>3.0.co;2-h · 1995
The national cancer data base report on bladder carcinoma
10.1002/(sici)1097-0142(19961001)78:7<1505::aid-cncr19>3.0.co;2-3 · 1996
Factors affecting recurrence and progression in superficial bladder tumours
10.1016/0959-8049(95)00287-s · 1995
Long term results of intravesical therapy for superficial bladder cancer
10.1016/s0094-0143(21)00424-9 · 1992
A combined analysis of EORTC and MRC randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer
10.1016/s0022-5347(01)65396-5 · 1996
Long-term results of intravesical chemoprophylaxis of superficial bladder cancer
10.1007/bf00686935 · 1992
Bacillus calmette-guerin therapy for superficial bladder cancer
10.1016/s0022-5347(17)37452-9 · 1992
Significant long-term patient benefit with BCG maintenance therapy
1997
Members of EORTC Genitourinary Group. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept
10.1046/j.1464-410x.1996.09002.x · 1996
Chemoresection in Ta-T1 bladder cancer
10.1159/000473784 · 1996
Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer
10.5980/jpnjurol1989.83.183 · 1992
Bladder Cancer BCG Study Group. Bacillus calmette-guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder
10.1002/1097-0142(19950115)75:2<552::aid-cncr2820750219>3.0.co;2-h · 1995
Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall
10.1016/s0022-5347(17)39365-5 · 1990
Intravesical evans strain BCG therapy
10.1016/s0022-5347(17)37668-1 · 1992
Neurophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration
10.1159/000473608 · 1991
Detection of urinary TNF, IL 1, and IL 2 after local BCG immunothrapy for bladder carcinoma
10.1016/1043-4666(90)90013-j · 1990
Induction of urinary IL 1, IL2, IL6, and TNF during intravesical immunotherapy with BCG in superficial bladder cancer
10.1007/bf01741551 · 1991
Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
10.1016/s0022-5347(01)66424-3 · 1996
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy
10.1016/s0022-5347(17)39713-6 · 1990
Interleukin 2 production during intravesical bacillus Calmette-Guérin therapy for bladder cancer
10.1016/0090-1229(86)90043-7 · 1986
Long-term immunobiological effects of intravesical bacillus calmette-guerin against bladder carcinoma recurrences
1992
Increase of HLA-AB and HLA-DR antigen expression on urothelial cells after BCG therapy
1993
BCG immunotherapy induces ICAM-1 expression on bladder tumors
10.1136/jcp.47.4.309 · 1994
Role of IL8 in onset of the BCG-induced immune response
10.1007/bf00941903 · 1997
Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guérin (BCG)
10.1007/bf00296835 · 1993
Suppressing effect of Lactobacillus casei administration on the urinary mutogenecity arising from injestion of fried ground beef in the human
10.1016/0304-3835(93)90261-7 · doi-reference
Effect of lactobacilli on urinary indican excretion in gnotobiotic rats and in men
10.1111/j.1348-0421.1981.tb00014.x · doi-reference
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rat
10.1159/000474484 · doi-reference
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial
10.1159/000475138 · doi-reference
Influence of Lactobacillus casei on rat bladder carcinogenesis
10.5980/jpnjurol1989.85.655 · doi-reference
Oral bropirimine immunotherapy of carcinoma in situ of the bladder
10.1016/s0090-4295(96)90059-x · doi-reference
Mycobacterium cell wall
10.1016/s0022-5347(01)65748-3 · doi-reference
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
10.1016/s0022-5347(17)35678-1 · doi-reference
Expression of antitumor response
10.1002/1097-0142(19930715)72:2<558::aid-cncr2820720237>3.0.co;2-h · doi-reference
Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro
10.1007/bf00184116 · doi-reference
Double fluorescent flow cytometric assessment of bacterial internalization and binding by epithelial cells
10.1002/(sici)1097-0320(19961201)25:4<381::aid-cyto10>3.0.co;2-r · doi-reference